A Phase 3 Study of Ivosidenib in People With Conventional Chondrosarcoma

Full Title

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants >/= 18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens (CHONQUER study)

Purpose

Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.

Ivosidenib blocks an abnormal form of the IDH1 protein. Abnormal IDH1 causes too much of a substance called 2-HG to be produced, which can fuel cancer growth. Ivosidenib is taken orally (by mouth).

If you join this study, you will be randomly assigned to get one of these treatments:

• Ivosidenib
• Placebo (inactive pill)

Contact

For more information or to see if you can join this study, please call Dr. William Tap at 646-888-4163.